AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company dedicated to pioneering precision medicine for neurodegenerative diseases. The company's mission is to diagnose, treat, and prevent conditions such as Alzheimer's disease, Parkinson's disease, and various NeuroOrphan indications driven by misfolded proteins. Headquartered in Lausanne, Switzerland, AC Immune was founded in 2003.

Leveraging its proprietary SupraAntigen® and Morphomer® technology platforms, AC Immune develops a diverse pipeline of therapeutic and diagnostic candidates. This pipeline includes active immunotherapies, antibodies, small molecule drugs, and diagnostic agents, with several programs currently in Phase 2 and Phase 3 clinical development. The company's research and development efforts are primarily focused on addressing the complexities of neurodegenerative diseases.

In March 2026, AC Immune reported its full-year 2025 financial results, highlighting positive interim Phase 2 data for ACI-7104, its wholly-owned active immunotherapy for Parkinson's disease, and the initiation of a Phase 1 trial for ACI-19764, an NLRP3 inhibitor. A strategic review in September 2025 led to a sharpened pipeline focus and a workforce reduction of approximately 30%, aimed at extending the company's cash runway into the third quarter of 2027. Dr. Andrea Pfeifer serves as the Chief Executive Officer. AC Immune maintains a strong track record of strategic partnerships with leading global pharmaceutical companies, including Janssen Pharmaceuticals, Takeda, and Eli Lilly.